[ad_1]
Hyderabad A German research institute and medical regulatory body, the Paul Ehrlich Institute (PEI), has approved clinical testing of a possible coronavirus vaccine, according to international media reports.
Permission to conduct human trials was given to a Mainz-based company BioNTech for its active substance, PEI announced.
According to BioNTech, the tests will be conducted on approximately 200 healthy volunteers. “Testing for possible vaccines in humans is an important milestone in producing safe and effective vaccines against Covid-19 for the population in Germany and beyond,” the German media told PEI. Approval is the result of a careful evaluation of the possible risk / benefit ratio of the possible vaccine.
A vaccine project must go through six stages: virus analysis; designing a vaccine; animal testing; volunteer trials, approval procedure and mass production.
Phase I / II clinical trials, among other things, will primarily test the tolerability and safety of the potential vaccine. The active substance developed by BioNTech is a gene-based vaccine. These substances contain genetic information about the pathogen. According to the report, this information is used in the body to make proteins against which the body’s immune system forms antibodies.
Now you can get carefully selected stories from Telangana today on Telegram every day. Click on the link to subscribe.
Click to follow the Telangana Today Facebook page and Twitter .
[ad_2]
